Evaxion Presents A New Source Of AI-derived Immunotherapeutic Targets Strongly Associated With The Overall Survival Of Cancer Patients

• Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy

• This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy

Evaxion Biotech A/S , a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies announces that it has developed a new proprietary AI platform technology ObsERV to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy.

Machine Learning Insights: Machine Learning in Supply Chain: KoiReader Technologies & NVIDIA Team Up To Simplify…

ObsERV, Evaxion’s new proprietary AI platform technology, identifies patient-specific virus targets, so-called ERVs (endogenous retroviruses), expressed in cancer. Evaxion has demonstrated that overexpression of such ERVs is strongly associated with the overall survival of cancer patients, notably of patients that are normally considered unresponsive to immunotherapy. In addition, the Company has preclinically demonstrated complete tumor eradication in animal models when targeting ERVs.

CEO Per Norlén:
“I am thrilled to share this exciting discovery, which may unlock the treatment of a much larger group of cancer patients. While there are efforts to develop cancer vaccines against ERVs that are shared between small groups of patients, we believe that we are the first in the world to use ERVs as targets for personalized cancer immunotherapy, broadening the scope tremendously.”

Read More about Generative AI : LinkedIn announces New Generative AI Tools for Recruiters

ERVs are remnants of ancient viruses lying dormant in our genomes. ERVs are often overexpressed in cancers but not in healthy tissue, making them visible to the immune system and hence a promising target for immunotherapy. Evaxion’s AI platforms for decoding the immune system have been the key to allowing the identification of patient-specific ERVs.

“Our AI platforms are continuously getting more powerful through machine learning. This ongoing, iterative improvement and the cross-pollination between our platforms for infectious disease and cancer has been essential for developing the new AI platform ObsERV. And it opens up a new treatment paradigm in cancer. Next step will be to turn this discovery into an AI-based drug development program that we intend to bring towards the clinic and to patients,” Per Norlén concludes.

 Latest AI Insights : Salesforce Announces New AI-powered Tableau Capabilities for Slack

 [To share your insights with us, please write to sghosh@martechseries.com]